Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 18/20 | 0.54 |
| ▸ | ITGB1 | P05556 | 17/20 | 0.54 |
| ▸ | ITGB7 | P26010 | 17/20 | 0.54 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.38 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.38 |
| ▸ | ITGAL | P20701 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21979211 | 1.00 | ITGA4 (0.54) | ITGA4ITGB1ITGB7ITGB2ICAM1 | |
| SCHEMBL22035500 | 0.94 | ITGB1 (0.47) | ITGA4ITGB1ITGB7ITGB2ICAM1 | |
| SCHEMBL29671131 | 0.94 | ITGB1 (0.47) | ITGA4ITGB1ITGB7ITGB2ICAM1 | |
| SCHEMBL21979355 | 0.93 | ITGB1 (0.48) | ITGA4ITGB1ITGB7ITGB2ICAM1 | |
| SCHEMBL21979352 | 0.93 | ITGB1 (0.48) | ITGA4ITGB1ITGB7ITGB2ICAM1 | |
| SCHEMBL22035517 | 0.92 | ITGA4 (0.52) | ITGA4ITGB1ITGB7ITGB2ICAM1 | |
| SCHEMBL21957315 | 0.91 | ITGB1 (0.49) | ITGA4ITGB1ITGB7ITGB2ICAM1 | |
| SCHEMBL21957313 | 0.91 | ITGB1 (0.49) | ITGA4ITGB1ITGB7ITGB2ICAM1 | |
| SCHEMBL22016617 | 0.91 | ITGB1 (0.49) | ITGA4ITGB1ITGB7ITGB2ICAM1 | |
| SCHEMBL21979042 | 0.90 | ITGB1 (0.44) | ITGA4ITGB1ITGB7ITGB2ICAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3873605-B1 | COMPOUNDS FOR INHIBITION OF ALPHA4BETA7 INTEGRIN | GILEAD SCIENCES INC (US) | 2024-10-23 | — | — | EP | disclosed |
| US-20220152014-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | GILEAD SCIENCES, INC. (US) | 2022-05-19 | — | — | US | disclosed |
| US-20220152014-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | GILEAD SCIENCES, INC. (US) | 2022-05-19 | — | — | US | disclosed |
| US-11179383-B2 | Compounds for inhibition of α4β7 integrin | GILEAD SCIENCES, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-11179383-B2 | Compounds for inhibition of α4β7 integrin | GILEAD SCIENCES, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| EP-3873605-A1 | COMPOUNDS FOR INHIBITION OF ALPHA4BETA7 INTEGRIN | GILEAD SCIENCES, INC. (US) | 2021-09-08 | — | — | EP | disclosed |
| US-20200163953-A1 | Compounds for Inhibition of Alpha 4 Beta 7 Integrin | GILEAD SCIENCES, INC. | 2020-05-28 | — | — | US | disclosed |
| US-20200163953-A1 | Compounds for Inhibition of Alpha 4 Beta 7 Integrin | GILEAD SCIENCES, INC. | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200163953-A1 | Compounds for Inhibition of Alpha 4 Beta 7 Integrin | ITGB7, ITGB4, ITGA4 | ITGA4 3/4885ITGB1 4/4885ITGB7 1/4885 |
| US-11179383-B2 | Compounds for inhibition of α4β7 integrin | ITGB7, ITGB4, ITGA4 | ITGA4 3/4885ITGB1 4/4885ITGB7 1/4885 |
| US-20220152014-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | ITGB7, ITGB4, ITGA4 | ITGA4 3/4885ITGB1 4/4885ITGB7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.